Our Manufacturing

Our proprietary cell characterization and manufacturing process is scalable, cost-effective and has been reviewed and cleared by the FDA for spinal cord administration.

Q Therapeutics has developed a multi-step isolation and purification process that yields a rich population of Q-Cells® (human glial-restricted progenitor cells). The core value proposition for our proprietary manufacturing process is our capability to cost-effectively produce a high-quality cellular therapeutic product with the economies of scale usually reserved for big pharma.

Each manufactured lot produces enough cells to treat hundreds of patients.

q-thera-q-cell-manufacturing-process.png
 
 Each vial of Q-Cells® contains millions of human glial progenitor cells, with the capacity to multiply and differentiate into millions of astrocytes and oligodendrocytes.